Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
Lee Steven Schwartzberg
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Research Funding - Eisai
Kurt W. Tauer
No relevant relationships to disclose
Robert C. Hermann
Consultant or Advisory Role - Genentech/Roche
Honoraria - Genentech/Roche
Research Funding - Eisai; Genentech/Roche
Petros G. Nikolinakos
No relevant relationships to disclose
Arthur C. Houts
No relevant relationships to disclose